♥

Divi's Laboratories Limited

ISIN : INE361B01024
NSE : DIVISLAB
BSE : 532488
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 60.27
EPS (TTM) : 63.06
Price to Earning (P/E) : 95.83
Book Value : 512.11
Price to Bookvalue (P/B) : 11.28
Dividend Yield : 1 %
Return on Equity (ROE) : 12.15 %
Return on Capital Employed (ROCE) : 16.46 %

Divi's Laboratories share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	5825.6 - 5857 0.5 %
Low / High	5648 - 5870.55 3.9 %
Trade Volume	17,791
52 Week Low / High	5637.5 - 7077.7 25.5 %

YOU MAY ALSO LIKE

CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Share Market basics for beginners
Share Market jargons in simple terms
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR DIVI'S LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	25184.4	22545.2	18545.4	17076.8	19507.7	17780	19090	18550	23030	21180
Total Income	25708.3	23429.1	19346.2	18219.3	20169.2	18590	19950	19500	23820	21970
Total Expenditure	14140.2	14078.2	12335	12994	14631.8	12740	14300	13660	15720	14960
Other Income	523.9	883.9	800.8	1142.5	661.5	810	860	950	790	790
Operating Profit	11568.1	9350.9	7011.2	5225.3	5537.4	5850	5650	5840	8100	7010
Interest	0.8	1.3	1.7	1.3	2.4		10		20
PBDT	11567.3	9349.6	7009.5	5224	5535	5850	5640	5840	8080	7010
Depreciation	809.9	836.6	857.3	867.7	870.2	930	950	950	950	970
Profit Before Tax	10757.4	8513	6152.2	4356.3	4664.8	4920	4690	4890	7130	6040
Tax	1811	1492.9	1216.2	1288.3	1455.1	1360	1210	1310	1750	1740
Profit After Tax	8946.4	7020.1	4936	3068	3209.7	3560	3480	3580	5380	4300
Net Profit	8946.4	7020.1	4936	3068	3209.7	3560	3480	3580	5380	4300
Equity Capital	530.9	530.9	530.9	530.9	530.9	530	530	530	530	530
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	33.7	26.45	18.59	11.56	12.09	13.43	13.13	13.51	20.3	16.23
Diluted Eps After Extraordinary Items	33.7	26.44	18.6	11.56	12.09	13.41	13.11	13.5	20.25	16.2
Diluted Eps Before Extraordinary Items	33.7	26.44	18.6	11.56	12.09	13.41	13.11	13.5	20.25	16.2

STANDALONE QUARTERLY RESULT FOR DIVI'S LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	24950.3	22039.2	18233.8	16898.3	19081.7	17300	18680	18080	22590	20630
Total Income	25455.4	22939.1	19026.3	18061.7	19743.2	18100	19530	19020	23380	21420
Total Expenditure	13990.6	13663.4	12141.2	12804.1	14194.7	12390	13940	13170	15420	14420
Other Income	505.1	899.9	792.5	1163.4	661.5	800	850	940	790	790
Operating Profit	11464.8	9275.7	6885.1	5257.6	5548.5	5710	5590	5850	7960	7000
Interest	0.4	1	1.3	1.1	1.8		10		20
PBDT	11464.4	9274.7	6883.8	5256.5	5546.7	5710	5580	5850	7940	7000
Depreciation	807.5	834.2	854.8	865.4	866.3	930	940	950	940	970
Profit Before Tax	10656.9	8440.5	6029	4391.1	4680.4	4780	4640	4900	7000	6030
Tax	1827.3	1524.4	1160.5	1282.1	1492.5	1330	1220	1320	1690	1730
Profit After Tax	8829.6	6916.1	4868.5	3109	3187.9	3450	3420	3580	5310	4300
Net Profit	8829.6	6916.1	4868.5	3109	3187.9	3450	3420	3580	5310	4300
Equity Capital	530.9	530.9	530.9	530.9	530.9	530	530	530	530	530
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	33.26	26.05	18.34	11.71	12.01	13.02	12.91	13.51	20.04	16.23
Diluted Eps After Extraordinary Items	33.26	26.05	18.34	11.71	12.01	12.99	12.89	13.5	19.99	16.18
Diluted Eps Before Extraordinary Items	33.26	26.05	18.34	11.71	12.01	12.99	12.89	13.5	19.99	16.18

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR DIVI'S LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	89598.3	77675.1	78450
Total Income	90737	81121.7	81840
Total Expenditure	50778.9	53996.9	56400
Other Income	1138.7	3446.6	3390
Operating Profit	39958.1	27124.8	25440
Interest	8	6.7	30
PBDT	39950.1	27118.1	25410
Depreciation	3115.1	3431.8	3780
Profit Before Tax	36835	23686.3	21630
Tax	7230.5	5452.5	5630
Profit After Tax	29604.5	18233.8	16000
Net Profit	29604.5	18233.8	16000
Equity Capital	530.9	530.9	530
Face Value (IN RS)	2	2	2
Reserves	116751	127140	135180
Calculated EPS	111.53	68.69	60.38
Diluted Eps After Extraordinary Items	111.52	68.69	60.27
Diluted Eps Before Extraordinary Items	111.52	68.69	60.27

STANDALONE ANNUAL RESULT FOR DIVI'S LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	88798.2	76253	76650
Total Income	89910.8	79743.1	80020
Total Expenditure	50033.6	52776.2	54910
Other Income	1112.6	3490.1	3370
Operating Profit	39877.2	26966.9	25110
Interest	6.5	5.2	30
PBDT	39870.7	26961.7	25080
Depreciation	3105.5	3420.7	3760
Profit Before Tax	36765.2	23541	21320
Tax	7279.8	5459.5	5560
Profit After Tax	29485.4	18081.5	15760
Net Profit	29485.4	18081.5	15760
Equity Capital	530.9	530.9	530
Face Value (IN RS)	2	2	2
Reserves	116383	126523	134310
Calculated EPS	111.08	68.12	59.47
Diluted Eps After Extraordinary Items	111.07	68.11	59.37
Diluted Eps Before Extraordinary Items	111.07	68.11	59.37

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR DIVI'S LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	6969.4 Cr	8988.19 Cr	7819.3 Cr	7891 Cr
Sales	6712.69 Cr	8816.47 Cr	7698.37 Cr	7829 Cr
Job Work/ Contract Receipts	145.65 Cr	11.12 Cr	19.36 Cr	13 Cr
Net Sales	6969.4 Cr	8959.83 Cr	7767.51 Cr	7845 Cr
Increase/Decrease in Stock	-78.67 Cr	-523.83 Cr	23.03 Cr	-109 Cr
Raw Material Consumed	2402.75 Cr	3490.97 Cr	3030.69 Cr	3238 Cr
Opening Raw Materials	507.06 Cr	705.51 Cr	773.02 Cr	972 Cr
Purchases Raw Materials	2595.89 Cr	3544.07 Cr	3207.03 Cr	3351 Cr
Closing Raw Materials	705.51 Cr	773.02 Cr	971.69 Cr	1091 Cr
Other Direct Purchases / Brought in cost	5.31 Cr	14.41 Cr	22.33 Cr	6 Cr
Power & Fuel Cost	319.15 Cr	392.33 Cr	496.61 Cr	477 Cr
Electricity & Power	319.15 Cr	392.33 Cr	496.61 Cr	477 Cr
Employee Cost	825.76 Cr	946.16 Cr	975.02 Cr	1094 Cr
Salaries, Wages & Bonus	789.99 Cr	898.43 Cr	922.45 Cr	1043 Cr
Contributions to EPF & Pension Funds	20.53 Cr	27.39 Cr	32.41 Cr	35 Cr
Workmen and Staff Welfare Expenses	15.24 Cr	20.34 Cr	20.16 Cr	16 Cr
Other Manufacturing Expenses	297.84 Cr	365.92 Cr	400.93 Cr	425 Cr
Processing Charges	26.54 Cr	27.56 Cr	27.09 Cr	27 Cr
Repairs and Maintenance	143.38 Cr	186.91 Cr	209.48 Cr	211 Cr
Packing Material Consumed	52.65 Cr	61.1 Cr	57.49 Cr	62 Cr
General and Administration Expenses	175.26 Cr	236.44 Cr	302.99 Cr	283 Cr
Rent , Rates & Taxes	23.33 Cr	27.67 Cr	26.84 Cr	29 Cr
Insurance	22.36 Cr	26.93 Cr	29.74 Cr	33 Cr
Printing and stationery	7.12 Cr	7.58 Cr	7.61 Cr	8 Cr
Professional and legal fees	11.5 Cr	10 Cr	16.56 Cr	22 Cr
Traveling and conveyance	31.77 Cr	50.3 Cr	90.96 Cr	56 Cr
Selling and Distribution Expenses	124.03 Cr	127.01 Cr	113.82 Cr	90 Cr
Advertisement & Sales Promotion	7 Lk	16 Lk	15 Lk	0
Sales Commissions & Incentives	12.89 Cr	13.41 Cr	11.44 Cr	11 Cr
Freight and Forwarding	111.07 Cr	113.44 Cr	102.23 Cr	79 Cr
Miscellaneous Expenses	42.11 Cr	43.72 Cr	55.31 Cr	141 Cr
Provision for doubtful debts	-11 Lk	0	33 Lk	4 Cr
Loss on disposal of fixed assets(net)	5.96 Cr	2.05 Cr	1.13 Cr	4 Cr
Loss on foreign exchange fluctuations	4.38 Cr	0	0	0
Total Expenditure	4108.23 Cr	5078.72 Cr	5398.4 Cr	5639 Cr
Other Income	62.56 Cr	115.9 Cr	344.66 Cr	339 Cr
Interest Received	57.24 Cr	68.96 Cr	204.59 Cr	301 Cr
Profits on sale of Investments	2.65 Cr	0	0	0
Provision Written Back	0	2.03 Cr	0	0
Foreign Exchange Gains	0	40.58 Cr	129.67 Cr	30 Cr
Operating Profit	2923.73 Cr	3997.01 Cr	2713.77 Cr	2545 Cr
Interest	2.1 Cr	2 Cr	1.96 Cr	4 Cr
Bank Charges etc	1.71 Cr	1.63 Cr	1.63 Cr	1 Cr
PBDT	2921.63 Cr	3995.01 Cr	2711.81 Cr	2541 Cr
Depreciation	255.59 Cr	311.51 Cr	343.18 Cr	378 Cr
Profit Before Taxation & Exceptional Items	2666.04 Cr	3683.5 Cr	2368.63 Cr	2163 Cr
Profit Before Tax	2666.04 Cr	3683.5 Cr	2368.63 Cr	2163 Cr
Provision for Tax	681.75 Cr	723.05 Cr	545.25 Cr	563 Cr
Current Income Tax	622.38 Cr	641.55 Cr	445.18 Cr	517 Cr
Deferred Tax	65.29 Cr	79.05 Cr	106.08 Cr	49 Cr
Profit After Tax	1984.29 Cr	2960.45 Cr	1823.38 Cr	1600 Cr
Consolidated Net Profit	1984.29 Cr	2960.45 Cr	1823.38 Cr	1600 Cr
Profit Balance B/F	5794.28 Cr	7597.72 Cr	9988.85 Cr	10959 Cr
Appropriations	7778.57 Cr	10558.2 Cr	11812.2 Cr	12559 Cr
Other Appropriation	180.85 Cr	569.32 Cr	854.12 Cr	773 Cr
Equity Dividend %	1000	1500	1500	1500
Earnings Per Share	74.75	111.53	68.69	60.38
Adjusted EPS	74.75	111.53	68.69	60.38

STANDALONE PROFIT / LOSS FOR DIVI'S LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	6798.61 Cr	8923.66 Cr	7677.09 Cr	7711 Cr
Sales	6541.9 Cr	8751.94 Cr	7556.16 Cr	7649 Cr
Job Work/ Contract Receipts	145.65 Cr	11.12 Cr	19.36 Cr	13 Cr
Net Sales	6798.61 Cr	8879.82 Cr	7625.3 Cr	7665 Cr
Increase/Decrease in Stock	-100 Cr	-449.99 Cr	50.16 Cr	-127 Cr
Raw Material Consumed	2365.5 Cr	3439.79 Cr	2979.49 Cr	3210 Cr
Opening Raw Materials	500.49 Cr	694.95 Cr	754.76 Cr	946 Cr
Purchases Raw Materials	2559.96 Cr	3499.6 Cr	3170.35 Cr	3331 Cr
Closing Raw Materials	694.95 Cr	754.76 Cr	945.62 Cr	1067 Cr
Power & Fuel Cost	319.15 Cr	390.05 Cr	496.61 Cr	477 Cr
Electricity & Power	319.15 Cr	390.05 Cr	496.61 Cr	477 Cr
Employee Cost	808.68 Cr	926.55 Cr	953.05 Cr	1067 Cr
Salaries, Wages & Bonus	772.91 Cr	882.02 Cr	903.87 Cr	1020 Cr
Contributions to EPF & Pension Funds	20.53 Cr	24.19 Cr	29.02 Cr	31 Cr
Workmen and Staff Welfare Expenses	15.24 Cr	20.34 Cr	20.16 Cr	16 Cr
Other Manufacturing Expenses	269.24 Cr	336.15 Cr	371.44 Cr	386 Cr
Repairs and Maintenance	143.38 Cr	186.91 Cr	209.48 Cr	211 Cr
Packing Material Consumed	50.97 Cr	59.39 Cr	55.53 Cr	60 Cr
General and Administration Expenses	166.34 Cr	211.22 Cr	280.38 Cr	270 Cr
Rent , Rates & Taxes	22.82 Cr	27.23 Cr	26.35 Cr	28 Cr
Insurance	21.58 Cr	26.02 Cr	28.99 Cr	32 Cr
Printing and stationery	6.62 Cr	7.01 Cr	6.96 Cr	7 Cr
Professional and legal fees	7.8 Cr	7.59 Cr	14.52 Cr	20 Cr
Traveling and conveyance	31.4 Cr	48.71 Cr	87.77 Cr	53 Cr
Selling and Distribution Expenses	110.21 Cr	107.56 Cr	90.34 Cr	70 Cr
Advertisement & Sales Promotion	7 Lk	8 Lk	6 Lk	0
Sales Commissions & Incentives	11.7 Cr	11.59 Cr	9.49 Cr	9 Cr
Freight and Forwarding	98.44 Cr	95.89 Cr	80.79 Cr	61 Cr
Miscellaneous Expenses	37.69 Cr	43.72 Cr	54.98 Cr	137 Cr
Provision for doubtful debts	-92 Lk	0	0	0
Loss on disposal of fixed assets(net)	5.96 Cr	2.05 Cr	1.13 Cr	4 Cr
Loss on foreign exchange fluctuations	77 Lk	0	0	0
Total Expenditure	3976.81 Cr	5005.05 Cr	5276.45 Cr	5490 Cr
Other Income	62.53 Cr	114.03 Cr	349.01 Cr	337 Cr
Interest Received	57.24 Cr	68.96 Cr	204.59 Cr	301 Cr
Profits on sale of Investments	2.65 Cr	0	0	0
Provision Written Back	0	2.77 Cr	0	0
Foreign Exchange Gains	0	37.98 Cr	134.02 Cr	28 Cr
Operating Profit	2884.33 Cr	3988.8 Cr	2697.86 Cr	2512 Cr
Interest	1.81 Cr	1.73 Cr	1.69 Cr	4 Cr
Bank Charges etc	1.6 Cr	1.51 Cr	1.51 Cr	1 Cr
PBDT	2882.52 Cr	3987.07 Cr	2696.17 Cr	2508 Cr
Depreciation	254.65 Cr	310.55 Cr	342.07 Cr	376 Cr
Profit Before Taxation & Exceptional Items	2627.87 Cr	3676.52 Cr	2354.1 Cr	2132 Cr
Profit Before Tax	2627.87 Cr	3676.52 Cr	2354.1 Cr	2132 Cr
Provision for Tax	673.15 Cr	727.98 Cr	545.95 Cr	556 Cr
Current Income Tax	615.8 Cr	634.39 Cr	438.18 Cr	514 Cr
Deferred Tax	64.1 Cr	90.78 Cr	108.37 Cr	45 Cr
Profit After Tax	1954.72 Cr	2948.54 Cr	1808.15 Cr	1576 Cr
Consolidated Net Profit	1954.72 Cr	2948.54 Cr	1808.15 Cr	1576 Cr
Profit Balance B/F	5814.44 Cr	7588.31 Cr	9967.53 Cr	10922 Cr
Appropriations	7769.16 Cr	10536.8 Cr	11775.7 Cr	12498 Cr
Other Appropriation	180.85 Cr	569.32 Cr	854.12 Cr	773 Cr
Equity Dividend %	1000	1500	1500	1500
Earnings Per Share	73.64	111.08	68.12	59.47
Adjusted EPS	73.64	111.08	68.12	59.47

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR DIVI'S LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	2666.04 Cr	3683.5 Cr	2368.63 Cr	2163 Cr
Adjustment	189.29 Cr	239.73 Cr	144.94 Cr	81 Cr
Changes In working Capital	-264.08 Cr	-1370.45 Cr	418.81 Cr	-607 Cr
Cash Flow after changes in Working Capital	2591.25 Cr	2552.78 Cr	2932.38 Cr	1637 Cr
Cash Flow from Operating Activities	1946.93 Cr	1911.8 Cr	2459.73 Cr	1261 Cr
Cash Flow from Investing Activities	75.13 Cr	-2194.92 Cr	-2707.62 Cr	-269 Cr
Cash Flow from Financing Activitie	-34.89 Cr	-532.44 Cr	-797.17 Cr	-799 Cr
Net Cash Inflow / Outflow	1987.17 Cr	-815.56 Cr	-1045.06 Cr	193 Cr
Opening Cash & Cash Equivalents	43.15 Cr	2030.32 Cr	1214.76 Cr	170 Cr
Closing Cash & Cash Equivalent	2030.32 Cr	1214.76 Cr	169.7 Cr	363 Cr

STANDALONE CASH FLOW FOR DIVI'S LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	2627.87 Cr	3676.52 Cr	2354.1 Cr	2132 Cr
Adjustment	186.66 Cr	235.32 Cr	118.14 Cr	72 Cr
Changes In working Capital	-234.52 Cr	-1371.89 Cr	447.3 Cr	-565 Cr
Cash Flow after changes in Working Capital	2580.01 Cr	2539.95 Cr	2919.54 Cr	1639 Cr
Cash Flow from Operating Activities	1947.05 Cr	1910.16 Cr	2447.95 Cr	1266 Cr
Cash Flow from Investing Activities	75.34 Cr	-2195.4 Cr	-2706.75 Cr	-268 Cr
Cash Flow from Financing Activitie	-33.97 Cr	-531.5 Cr	-796.59 Cr	-798 Cr
Net Cash Inflow / Outflow	1988.42 Cr	-816.74 Cr	-1055.39 Cr	200 Cr
Opening Cash & Cash Equivalents	27.88 Cr	2016.3 Cr	1199.56 Cr	144 Cr
Closing Cash & Cash Equivalent	2016.3 Cr	1199.56 Cr	144.17 Cr	344 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR DIVI'S LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	53.09 Cr	53.09 Cr	53.09 Cr	53 Cr
Equity - Authorised	60 Cr	60 Cr	60 Cr	60 Cr
Equity - Issued	53.09 Cr	53.09 Cr	53.09 Cr	53 Cr
Equity Paid Up	53.09 Cr	53.09 Cr	53.09 Cr	53 Cr
Face Value	2	2	2	2
Total Reserves	9241.52 Cr	11675.1 Cr	12714 Cr	13518 Cr
Securities Premium	79.88 Cr	79.88 Cr	79.88 Cr	80 Cr
Profit & Loss Account Balance	7597.72 Cr	9988.85 Cr	10958.1 Cr	11786 Cr
General Reserves	1000 Cr	1000 Cr	1000 Cr	1000 Cr
Reserve excluding Revaluation Reserve	9241.52 Cr	11675.1 Cr	12714 Cr	13518 Cr
Shareholder's Funds	9294.61 Cr	11728.2 Cr	12767.1 Cr	13571 Cr
Deferred Tax Assets / Liabilities	334.83 Cr	406.93 Cr	522.97 Cr	572 Cr
Deferred Tax Assets	16.27 Cr	36.04 Cr	29.91 Cr	30 Cr
Deferred Tax Liability	351.1 Cr	442.97 Cr	552.88 Cr	602 Cr
Other Long Term Liabilities	3.69 Cr	2.87 Cr	2.77 Cr	2 Cr
Long Term Provisions	25.42 Cr	26.71 Cr	30.62 Cr	37 Cr
Total Non-Current Liabilities	363.94 Cr	436.51 Cr	556.36 Cr	611 Cr
Trade Payables	763.2 Cr	795.7 Cr	762.51 Cr	824 Cr
Sundry Creditors	763.2 Cr	795.7 Cr	762.51 Cr	824 Cr
Other Current Liabilities	340.42 Cr	394.02 Cr	331.44 Cr	404 Cr
Advances received from customers	16.06 Cr	16.63 Cr	32.72 Cr	34 Cr
Short Term Borrowings	35 Lk	0	0	0
Secured ST Loans repayable on Demands	35 Lk	0	0	0
Working Capital Loans- Sec	35 Lk	0	0	0
Short Term Provisions	624.38 Cr	1264.72 Cr	439.13 Cr	527 Cr
Provision for Tax	621.87 Cr	1260.57 Cr	434.21 Cr	520 Cr
Total Current Liabilities	1728.35 Cr	2454.44 Cr	1533.08 Cr	1755 Cr
Total Liabilities	11386.9 Cr	14619.1 Cr	14856.5 Cr	15937 Cr
Gross Block	4691.86 Cr	5624.27 Cr	6364.76 Cr	6760 Cr
Less: Accumulated Depreciation	987.99 Cr	1299.22 Cr	1642.16 Cr	2021 Cr
Net Block	3703.87 Cr	4325.05 Cr	4722.6 Cr	4739 Cr
Capital Work in Progress	710.62 Cr	469.93 Cr	211.88 Cr	778 Cr
Non Current Investments	1 Lk	72.01 Cr	77.05 Cr	82 Cr
Long Term Investment	1 Lk	72.01 Cr	77.05 Cr	82 Cr
Unquoted	1 Lk	72.01 Cr	77.05 Cr	82 Cr
Long Term Loans & Advances	172.59 Cr	133.7 Cr	97.61 Cr	176 Cr
Other Non Current Assets	9.21 Cr	8.05 Cr	3.65 Cr	10 Cr
Total Non-Current Assets	4596.3 Cr	5008.74 Cr	5112.79 Cr	5785 Cr
Unquoted	1 Lk	72.01 Cr	77.05 Cr	82 Cr
Inventories	2145.23 Cr	2828.62 Cr	3000.41 Cr	3184 Cr
Raw Materials	705.51 Cr	773.02 Cr	971.69 Cr	1091 Cr
Work-in Progress	1093.34 Cr	1531.59 Cr	1525.71 Cr	1620 Cr
Finished Goods	99.36 Cr	154.21 Cr	175.12 Cr	150 Cr
Packing Materials	8.38 Cr	9.16 Cr	9.36 Cr	8 Cr
Stores and Spare	104.43 Cr	195.7 Cr	191.65 Cr	148 Cr
Sundry Debtors	1676.52 Cr	2423.88 Cr	1792.53 Cr	2156 Cr
Debtors more than Six months	0	10.08 Cr	10.18 Cr	18 Cr
Debtors Others	1682.07 Cr	2418.92 Cr	1788.22 Cr	2148 Cr
Cash and Bank	2156.03 Cr	2818.88 Cr	4213.09 Cr	3980 Cr
Cash in hand	75 Lk	71 Lk	92 Lk	1 Cr
Balances at Bank	2155.28 Cr	2818.17 Cr	4212.17 Cr	3979 Cr
Other Current Assets	128.42 Cr	29.69 Cr	28.97 Cr	38 Cr
Prepaid Expenses	22.5 Cr	27.09 Cr	27.2 Cr	36 Cr
Short Term Loans and Advances	684.4 Cr	1509.32 Cr	708.74 Cr	794 Cr
Advances recoverable in cash or in kind	31.16 Cr	87.31 Cr	33.89 Cr	80 Cr
Advance income tax and TDS	650.16 Cr	1316.57 Cr	529.87 Cr	505 Cr
Total Current Assets	6790.6 Cr	9610.39 Cr	9743.74 Cr	10152 Cr
Net Current Assets (Including Current Investments)	5062.25 Cr	7155.95 Cr	8210.66 Cr	8397 Cr
Total Assets	11386.9 Cr	14619.1 Cr	14856.5 Cr	15937 Cr
Contingent Liabilities	7.06 Cr	89.03 Cr	89.03 Cr	257 Cr
Total Debt	35 Lk	0	0	0
Book Value	350.15	441.82	480.96	512.11
Adjusted Book Value	350.15	441.82	480.96	512.11

STANDALONE BALANCE SHEET FOR DIVI'S LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	53.09 Cr	53.09 Cr	53.09 Cr	53 Cr
Equity - Authorised	60 Cr	60 Cr	60 Cr	60 Cr
Equity - Issued	53.09 Cr	53.09 Cr	53.09 Cr	53 Cr
Equity Paid Up	53.09 Cr	53.09 Cr	53.09 Cr	53 Cr
Face Value	2	2	2	2
Total Reserves	9218.48 Cr	11638.3 Cr	12652.3 Cr	13431 Cr
Securities Premium	79.88 Cr	79.88 Cr	79.88 Cr	80 Cr
Profit & Loss Account Balance	7588.31 Cr	9967.53 Cr	10921.6 Cr	11725 Cr
General Reserves	1000 Cr	1000 Cr	1000 Cr	1000 Cr
Reserve excluding Revaluation Reserve	9218.48 Cr	11638.3 Cr	12652.3 Cr	13431 Cr
Shareholder's Funds	9271.57 Cr	11691.4 Cr	12705.4 Cr	13484 Cr
Deferred Tax Assets / Liabilities	338.06 Cr	421.4 Cr	537.21 Cr	582 Cr
Deferred Tax Assets	13.04 Cr	21.57 Cr	15.67 Cr	20 Cr
Deferred Tax Liability	351.1 Cr	442.97 Cr	552.88 Cr	602 Cr
Long Term Provisions	25.42 Cr	26.71 Cr	30.62 Cr	37 Cr
Total Non-Current Liabilities	363.48 Cr	448.11 Cr	567.83 Cr	619 Cr
Trade Payables	748.78 Cr	771.3 Cr	742.64 Cr	807 Cr
Sundry Creditors	748.78 Cr	771.3 Cr	742.64 Cr	807 Cr
Other Current Liabilities	337.25 Cr	392.95 Cr	330.81 Cr	403 Cr
Advances received from customers	16.06 Cr	16.63 Cr	32.72 Cr	34 Cr
Short Term Borrowings	35 Lk	0	0	0
Secured ST Loans repayable on Demands	35 Lk	0	0	0
Working Capital Loans- Sec	35 Lk	0	0	0
Short Term Provisions	618.4 Cr	1263.04 Cr	436.92 Cr	520 Cr
Provision for Tax	615.89 Cr	1258.89 Cr	432 Cr	513 Cr
Total Current Liabilities	1704.78 Cr	2427.29 Cr	1510.37 Cr	1730 Cr
Total Liabilities	11339.8 Cr	14566.8 Cr	14783.6 Cr	15833 Cr
Gross Block	4685.46 Cr	5617.69 Cr	6357.25 Cr	6752 Cr
Less: Accumulated Depreciation	986.45 Cr	1296.72 Cr	1638.49 Cr	2015 Cr
Net Block	3699.01 Cr	4320.97 Cr	4718.76 Cr	4737 Cr
Capital Work in Progress	710.62 Cr	469.93 Cr	211.88 Cr	778 Cr
Non Current Investments	7.37 Cr	79.37 Cr	84.41 Cr	89 Cr
Long Term Investment	7.37 Cr	79.37 Cr	84.41 Cr	89 Cr
Unquoted	7.37 Cr	79.37 Cr	84.41 Cr	89 Cr
Long Term Loans & Advances	172.42 Cr	133.58 Cr	97.47 Cr	176 Cr
Other Non Current Assets	9.21 Cr	8.05 Cr	3.65 Cr	10 Cr
Total Non-Current Assets	4598.63 Cr	5011.9 Cr	5116.17 Cr	5790 Cr
Unquoted	7.37 Cr	79.37 Cr	84.41 Cr	89 Cr
Inventories	2042.7 Cr	2644.05 Cr	2780.45 Cr	2985 Cr
Raw Materials	694.95 Cr	754.76 Cr	945.62 Cr	1067 Cr
Work-in Progress	1093.34 Cr	1531.59 Cr	1525.71 Cr	1620 Cr
Finished Goods	14.25 Cr	10.86 Cr	4.63 Cr	4 Cr
Packing Materials	8.38 Cr	9.16 Cr	9.36 Cr	8 Cr
Stores and Spare	103.4 Cr	194.17 Cr	189.67 Cr	147 Cr
Sundry Debtors	1745.56 Cr	2569.9 Cr	1964.3 Cr	2273 Cr
Debtors more than Six months	0	2.69 Cr	42.45 Cr	17 Cr
Debtors Others	1747.65 Cr	2567.93 Cr	1922.57 Cr	2257 Cr
Cash and Bank	2142.01 Cr	2803.68 Cr	4187.56 Cr	3961 Cr
Cash in hand	75 Lk	70 Lk	90 Lk	1 Cr
Balances at Bank	2141.26 Cr	2802.98 Cr	4186.66 Cr	3960 Cr
Other Current Assets	122.39 Cr	29.36 Cr	28.21 Cr	37 Cr
Prepaid Expenses	22.18 Cr	26.76 Cr	26.44 Cr	35 Cr
Short Term Loans and Advances	688.54 Cr	1507.86 Cr	706.93 Cr	787 Cr
Advances recoverable in cash or in kind	31.16 Cr	87.22 Cr	33.81 Cr	80 Cr
Advance income tax and TDS	650.16 Cr	1316.57 Cr	529.87 Cr	499 Cr
Total Current Assets	6741.2 Cr	9554.85 Cr	9667.45 Cr	10043 Cr
Net Current Assets (Including Current Investments)	5036.42 Cr	7127.56 Cr	8157.08 Cr	8313 Cr
Total Assets	11339.8 Cr	14566.8 Cr	14783.6 Cr	15833 Cr
Contingent Liabilities	7.06 Cr	89.03 Cr	89.03 Cr	257 Cr
Total Debt	35 Lk	0	0	0
Book Value	349.28	440.44	478.64	508.83
Adjusted Book Value	349.28	440.44	478.64	508.83

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR DIVI'S LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	74.75	111.53	68.69	60.38
CEPS(Rs)	84.38	123.26	81.62	74.64
DPS(Rs)	20	30	30	30
Book NAV/Share(Rs)	350.15	441.82	480.96	512.11
Tax Rate(%)	25.57	19.63	23.02	26.03
Margin Ratios
Core EBITDA Margin(%)	41.05	43.18	30.3	27.96
EBIT Margin(%)	38.28	41	30.32	27.46
Pre Tax Margin(%)	38.25	40.98	30.29	27.41
PAT Margin (%)	28.47	32.94	23.32	20.28
Cash Profit Margin (%)	32.14	36.4	27.71	25.07
Performance Ratios
ROA(%)	19.07	22.77	12.37	10.39
ROE(%)	23.9	28.16	14.89	12.15
ROCE(%)	32.07	35.06	19.36	16.46
Asset Turnover(x)	0.67	0.69	0.53	0.51
Sales/Fixed Asset(x)	1.7	1.74	1.3	1.2
Working Capital/Sales(x)	1.38	1.26	0.95	0.94
Efficiency Ratios
Fixed Capital/Sales(x)	0.59	0.57	0.77	0.83
Receivable days	80.91	83.26	98.41	91.33
Inventory Days	104.98	100.99	136.05	143.02
Payable days	59.72	95.88	93.12	92.5
Valuation Parameters
PER(x)	48.56	39.49	41.14	56.92
PCE(x)	43.02	35.73	34.62	46.04
Price/Book(x)	10.37	9.97	5.88	6.71
Yield(%)	0.55	0.68	1.06	0.87
EV/Net Sales(x)	13.52	12.73	9.11	11.1
EV/Core EBITDA(x)	32.22	28.54	26.09	34.22
EV/EBIT(x)	35.31	30.95	29.86	40.19
EV/CE(x)	8.27	7.8	4.77	6.42
M Cap / Sales	13.83	13.05	9.66	11.61
Growth Ratio
Net Sales Growth(%)	29.2	28.56	-13.31	1
Core EBITDA Growth(%)	45.25	36.71	-32.11	-6.23
EBIT Growth(%)	46.07	38.13	-35.68	-8.6
PAT Growth(%)	44.15	49.19	-38.41	-12.28
EPS Growth(%)	44.15	49.19	-38.41	-12.28
Financial Stability Ratios
Current Ratio(x)	3.93	3.92	6.36	5.78
Quick Ratio(x)	2.69	2.76	4.4	3.97
Interest Cover(x)	1270.54	1842.75	1209.48	541.75

FINANCIAL RATIOS (STANDALONE) FOR DIVI'S LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	73.64	111.08	68.12	59.47
CEPS(Rs)	83.23	122.78	81	73.66
DPS(Rs)	20	30	30	30
Book NAV/Share(Rs)	349.28	440.44	478.64	508.83
Tax Rate(%)	25.62	19.8	23.19	26.08
Margin Ratios
Core EBITDA Margin(%)	41.51	43.42	30.6	28.21
EBIT Margin(%)	38.68	41.22	30.69	27.7
Pre Tax Margin(%)	38.65	41.2	30.66	27.65
PAT Margin (%)	28.75	33.04	23.55	20.44
Cash Profit Margin (%)	32.5	36.52	28.01	25.31
Performance Ratios
ROA(%)	18.84	22.76	12.32	10.29
ROE(%)	23.57	28.13	14.82	12.04
ROCE(%)	31.64	35.09	19.31	16.31
Asset Turnover(x)	0.66	0.69	0.52	0.5
Sales/Fixed Asset(x)	1.66	1.73	1.28	1.18
Working Capital/Sales(x)	1.35	1.25	0.94	0.93
Efficiency Ratios
Fixed Capital/Sales(x)	0.6	0.58	0.78	0.85
Receivable days	88.01	88.26	107.79	100.28
Inventory Days	101.65	95.85	128.95	136.47
Payable days	60.06	92.79	91.2	91.75
Valuation Parameters
PER(x)	49.3	39.65	41.48	57.79
PCE(x)	43.61	35.87	34.88	46.66
Price/Book(x)	10.39	10	5.9	6.75
Yield(%)	0.55	0.68	1.06	0.87
EV/Net Sales(x)	13.86	12.85	9.29	11.37
EV/Core EBITDA(x)	32.67	28.6	26.25	34.68
EV/EBIT(x)	35.83	31.02	30.06	40.78
EV/CE(x)	8.31	7.83	4.79	6.46
M Cap / Sales	14.17	13.16	9.84	11.88
Growth Ratio
Net Sales Growth(%)	28.02	30.61	-14.13	0.52
Core EBITDA Growth(%)	43.77	38.29	-32.36	-6.89
EBIT Growth(%)	44.46	39.87	-35.95	-9.34
PAT Growth(%)	42.4	50.84	-38.68	-12.83
EPS Growth(%)	42.4	50.84	-38.68	-12.83
Financial Stability Ratios
Current Ratio(x)	3.95	3.94	6.4	5.81
Quick Ratio(x)	2.76	2.85	4.56	4.08
Interest Cover(x)	1452.86	2126.16	1393.96	534

SHARE HOLDING PATTERN FOR DIVI'S LABORATORIES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	51.94	51.94	51.94	51.94	51.93	51.93	51.92	51.92	51.90	51.89
FII %	16.52	15.40	15.15	14.67	14.69	14.60	14.85	14.68	16.16	17.25
DII %	0.47	0.48	0.32	0.33	0.29	0.28	0.32	0.31	0.32	0.29
Public %	11.56	11.87	12.24	12.31	12.14	11.73	11.34	11.19	10.18	9.80

PEER COMPARISON FOR DIVI'S LABORATORIES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR DIVI'S LABORATORIES

Exchange Date	Purpose	Book Closure Dates
BSE 29-Oct-2024	Board Meeting - Quarterly Results	09-Nov-2024
BSE 25-Jul-2024	Board Meeting - Quarterly Results	03-Aug-2024
BSE 27-May-2024	Dividend - Rs.30.0000 per share(1500%)Final Dividend
BSE 15-May-2024	Board Meeting - Dividend & Audited Results	25-May-2024
BSE 30-Jan-2024	Board Meeting - Quarterly Results	10-Feb-2024
BSE 26-Oct-2023	Board Meeting - Quarterly Results	06-Nov-2023
BSE 07-Aug-2023	Board Meeting - Quarterly Results	14-Aug-2023
BSE 22-May-2023	Dividend - Rs.30.0000 per share(1500%)Final Dividend
BSE 12-May-2023	Board Meeting - Final Dividend & Audited Results	20-May-2023
BSE 23-Jan-2023	Board Meeting - Quarterly Results	03-Feb-2023
BSE 28-Oct-2022	Board Meeting - Quarterly Results	07-Nov-2022
BSE 28-Jul-2022	AGM - As already informed vide our letter dated July 04, 2022, the 32nd Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, August 22, 2022at 10.00 a.m. IST through video conferencing (VC) / other audio-visual means (OAVM). Pursuant to Regulation 34 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015, please find enclosed Notice convening the 32nd AG...	22-Aug-2022
BSE 28-Jul-2022	Board Meeting - Quarterly Results	12-Aug-2022
BSE 23-May-2022	Dividend - Rs.30.0000 per share(1500%)Dividend
BSE 13-May-2022	Board Meeting - Dividend & Audited Results	23-May-2022
BSE 01-Feb-2022	Board Meeting - Quarterly Results (Revised)	11-Feb-2022
BSE 25-Jan-2022	Board Meeting - Quarterly Results	04-Feb-2022
BSE 28-Oct-2021	Board Meeting - Quarterly Results	06-Nov-2021

CORPORATE ANNOUNCEMENTS FOR DIVI'S LABORATORIES

Exchange Date	Category File	Description
BSE 29-Oct-2024	Intimation FILE	Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2024. DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended September 30 2024.
BSE 10-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Submission of certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended September 30 2024.
BSE 30-Sep-2024	Intimation FILE	Closure of Trading Window Intimation of closure of Trading Window from October 01 2024 till 48 hours of declaration of financial results of the Company for the quarter and half year ended September 30 2024.
BSE 14-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Credit Rating Intimation of reaffirmation of credit rating.
BSE 12-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Please find the enclosed scrutinizers report on the AGM resolutions along with proceedings of the AGM and Voting results.
BSE 12-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Please find the enclosed proceedings of the 34th Annual General Meeting voting results and report of scrutinizer on the AGM resolutions.
BSE 08-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of earnings conference call held on August 03 2024.
BSE 05-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication of extracts of unaudited financial results for the quarter ended June 30 2024.
BSE 03-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio recording of Q1 FY25 earnings conference call held on August 03 2024.
BSE 03-Aug-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter Ended June 30 2024 Further to our intimation dated July 25 2024 we would like to inform that the Board of Directors of the Company at its meeting held on August 03 2024 has approved the unaudited financial results for the quarter ended June 30 2024. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the following:1. Statement of standalone unaudited financial results for the quarter ended June 30 2024 and Limited Review Report of the Statutory Auditors thereon.2. Statement of consolidated unaudited financial results for the quarter ended June 30 2024 and Limited Review Report of the Statutory Auditors thereon.3. Press release on the financial results of the Company.
BSE 03-Aug-2024	Outcome FILE	Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter Ended June 30 2024 As per enclosed letter.
BSE 27-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of schedule of earnings conference call for Q1FY25 to be held on August 03 2024 at 14:00 Hrs (IST).
BSE 25-Jul-2024	Intimation FILE	Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30 2024. DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended June 30 2024.
BSE 19-Jul-2024	General Announcements FILE	US-FDA Inspection Of Company'S Unit-II Manufacturing Facility At Visakhapatnam Andhra Pradesh As per enclosed letter.
BSE 17-Jul-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 As per enclosed letter.
BSE 17-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication regarding 34th AGM E-voting and other information.
BSE 15-Jul-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report for the financial year ended March 31 2024.
BSE 15-Jul-2024	Intimation FILE	Notice Of 34Th Annual General Meeting To Be Held On Monday August 12 2024 At 10.00 A.M. IST Through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) Please find the enclosed Notice of 34th Annual General Meeting of the Company.
BSE 15-Jul-2024	General Announcements FILE	Reg. 34 (1) Annual Report. The 34th Annual General Meeting (AGM) of the Company is scheduled to be held on Monday August 12 2024 at 10.00 a.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed Notice convening the 34th AGM of the Company and Annual Report for the financial year 2023-24 being sent to the members through electronic mode. The Annual Report 2023-24 containing the Notice of the 34th AGM is also uploaded on the Companys website at https://www.divislabs.com/investor-relations/reports-and-filings/annual-reporting/.
BSE 13-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Clippings related to notice to shareholders regarding 34th Annual General Meeting Record date for dividend and other information
BSE 29-Jun-2024	Intimation FILE	Closure of Trading Window Intimation of Trading Window closure from July 01 2024 till 48 hours after the declaration of unaudited financial results of the Company for the quarter ending June 30 2024.
BSE 22-Jun-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Cessation Intimation of completion of tenure of Mr. K.V. K. Seshavataram as Independent Director of the Company w.e.f. 22.06.2024.
BSE 22-Jun-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Cessation Intimation of completion of tenure of Mr. K.V.K. Seshavataram as Independent Director of the Company on June 22 2024.
BSE 20-Jun-2024	General Announcements FILE	Communication To Shareholders - Information Regarding Deduction Of Income Tax At Source From Payment Of Dividend For The Financial Year 2023-24 As per enclsoed letter.
BSE 30-May-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of Q4FY24 earnings call held on May 25 2024.
BSE 27-May-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Copies of Newspaper Publication regarding extracts of Audited Financial Results of the Company for the quarter and year ended March 31 2024.
BSE 25-May-2024	General Announcements FILE	Compliance Of Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As per enclosed letter.
BSE 25-May-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Submission of weblink of Audio recording of earnings conference call Q4FY2024 held on May 25 2024.
BSE 25-May-2024	Outcome FILE	Corporate Action-Board approves Dividend As per enclosed letter.
BSE 25-May-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate As per enclosed letter.

INSIDER TRADING FOR DIVI'S LABORATORIES

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 27-Sep-2024 27-Sep-2024	Sell Market	750 @ 0.00 (0.00 %)	Y KAMALAKAR
BSE 11-Sep-2024 11-Sep-2024	Sell Market	100 @ 0.00 (0.00 %)	K Sridevi
BSE 05-Sep-2024 05-Sep-2024	Sell Market	250 @ 0.00 (0.00 %)	K Sridevi
BSE 29-Aug-2024 29-Aug-2024	Buy Gift	2,700 @ 0.00 (0.00 %)	A Lakshmi
BSE 29-Aug-2024 29-Aug-2024	Sell Gift	2,700 @ 0.00 (0.00 %)	AML Punna Rao
BSE 28-Aug-2024 30-Aug-2024	Sell Market	600 @ 0.00 (0.00 %)	K Sridevi
BSE 28-Aug-2024 28-Aug-2024	Sell Market	13,808 @ 0.00 (0.01 %)	Nimmagadda Venkata Anirudh
BSE 26-Aug-2024 26-Aug-2024	Sell Market	10,000 @ 0.00 (0.00 %)	Nimmagadda Venkata Anirudh
BSE 23-Aug-2024 26-Aug-2024	Sell Market	2,000 @ 0.00 (0.00 %)	M Ramesh Babu
BSE 07-Aug-2024 07-Aug-2024	Sell Market	12,000 @ 0.00 (0.01 %)	Divi Madhusudana Rao
BSE 25-Jun-2024 28-Jun-2024	Sell Market	850 @ 0.00 (0.00 %)	Y RAMA DEVI
BSE 28-Jun-2024 28-Jun-2024	Sell Market	200 @ 0.00 (0.00 %)	M Visweswara Rao
BSE 14-Jun-2024 17-Jun-2024	Sell Market	1,000 @ 0.00 (0.00 %)	M Ramesh Babu
BSE 13-Jun-2024 14-Jun-2024	Sell Market	10,000 @ 0.00 (0.01 %)	Nimmagadda Venkata Anirudh
BSE 31-May-2024 10-Jun-2024	Sell Market	200 @ 0.00 (0.00 %)	B Sreelakshimi
BSE 11-Jun-2024 13-Jun-2024	Sell Market	500 @ 0.00 (0.00 %)	Yalavarthi Vamsi Krishna
BSE 29-May-2024 05-Jun-2024	Sell Market	750 @ 0.00 (0.00 %)	B Laxminarayana
BSE 05-Jun-2024 05-Jun-2024	Sell Market	250 @ 0.00 (0.00 %)	K Sridevi
BSE 31-May-2024 31-May-2024	Sell Market	6,940 @ 0.00 (0.00 %)	Y KAMALAKAR
BSE 30-May-2024 31-May-2024	Sell Market	400 @ 0.00 (0.00 %)	Ch Venu
BSE 30-May-2024 30-May-2024	Sell Market	2,600 @ 0.00 (0.01 %)	DIVI MADHUSUDANA RAO
BSE 29-May-2024 29-May-2024	Sell Market	500 @ 0.00 (0.00 %)	N Ravi Kumar
BSE 07-Mar-2024 28-Mar-2024	Sell Market	500 @ 0.00 (0.00 %)	Y Sreedevi
BSE 12-Mar-2024 14-Mar-2024	Sell Market	2,000 @ 0.00 (0.00 %)	Sirisha V
BSE 13-Feb-2024 14-Feb-2024	Sell Market	15,000 @ 0.00 (0.01 %)	P Srinivas Rao
BSE 29-Dec-2023 29-Dec-2023	Sell Market	5,000 @ 0.00 (0.00 %)	DIVI MADHUSUDANA RAO
BSE 28-Dec-2023 28-Dec-2023	Sell Market	3,500 @ 0.00 (0.00 %)	Y KAMALAKAR
BSE 28-Dec-2023 28-Dec-2023	Sell Market	800 @ 0.00 (0.00 %)	M Visweswara Rao
BSE 27-Dec-2023 28-Dec-2023	Sell Market	1,000 @ 0.00 (0.00 %)	B Laxminarayana
BSE 27-Dec-2023 28-Dec-2023	Sell Market	15,000 @ 0.00 (0.01 %)	Divi Madhusudana Rao

BULK BLOCK DEALS FOR DIVI'S LABORATORIES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 20-Oct-2023	Buy BLOCK	43,478 @ 3637.70	NORTHERN LIGHTS FUND TRUST III RONDURE NEW WORLD FUND
BSE 20-Oct-2023	Sell BLOCK	43,478 @ 3637.70	RONDURE NEW WORLD FUND
BSE 25-Oct-2022	Sell BLOCK	112,509 @ 3612.00	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 25-Oct-2022	Buy BLOCK	112,509 @ 3612.00	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 17-Oct-2022	Sell BLOCK	176,805 @ 3572.80	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 17-Oct-2022	Buy BLOCK	176,805 @ 3572.80	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 11-Oct-2022	Sell BLOCK	172,889 @ 3686.60	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 11-Oct-2022	Buy BLOCK	172,889 @ 3686.60	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	117,596 @ 3573.70	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	117,596 @ 3573.70	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 01-Aug-2022	Sell BLOCK	156,778 @ 3831.65	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 01-Aug-2022	Buy BLOCK	156,778 @ 3831.65	ISHARES MSCI INDIA ETF
BSE 18-Jul-2022	Buy BLOCK	20,608 @ 3727.75	ISHARES INDIA 50 ETF
BSE 18-Jul-2022	Sell BLOCK	157,719 @ 3727.75	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 18-Jul-2022	Sell BLOCK	20,608 @ 3727.75	ISHARES INDIA MAURITIUS CO
BSE 18-Jul-2022	Buy BLOCK	157,719 @ 3727.75	ISHARES MSCI INDIA ETF
BSE 04-May-2022	Buy BLOCK	160,057 @ 4509.65	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	160,057 @ 4509.65	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO
BSE 20-Oct-2021	Sell BLOCK	123,256 @ 5192.10	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 20-Oct-2021	Buy BLOCK	123,256 @ 5192.10	ISHARES MSCI EMERGING MARKETS ETF
BSE 11-Oct-2021	Sell BLOCK	123,257 @ 5071.30	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 11-Oct-2021	Buy BLOCK	123,257 @ 5071.30	ISHARES MSCI EMERGING MARKETS ETF
BSE 04-Oct-2021	Sell BLOCK	126,724 @ 4832.30	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 04-Oct-2021	Buy BLOCK	126,724 @ 4832.30	ISHARES MSCI EMERGING MARKETS ETF
BSE 23-Sep-2021	Sell BLOCK	125,459 @ 5139.90	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 23-Sep-2021	Buy BLOCK	125,459 @ 5139.90	ISHARES MSCI EMERGING MARKETS ETF

DIVIDEND BY DIVI'S LABORATORIES LIMITED

Ex Dividend Date	Dividend Type	Dividend
02-Aug-2024	DIVIDEND	30
11-Aug-2023	DIVIDEND	30
11-Aug-2022	DIVIDEND	30
17-Aug-2021	DIVIDEND	20

SPLIT / BONUS BY DIVI'S LABORATORIES LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Divi's Laboratories Limited

Divi's Laboratories share price

CONSOLIDATED QUARTERLY RESULT FOR DIVI'S LABORATORIES LIMITED

STANDALONE QUARTERLY RESULT FOR DIVI'S LABORATORIES LIMITED

CONSOLIDATED ANNUAL RESULT FOR DIVI'S LABORATORIES LIMITED

STANDALONE ANNUAL RESULT FOR DIVI'S LABORATORIES LIMITED

CONSOLIDATED PROFIT / LOSS FOR DIVI'S LABORATORIES LIMITED

STANDALONE PROFIT / LOSS FOR DIVI'S LABORATORIES LIMITED

CONSOLIDATED CASH FLOW FOR DIVI'S LABORATORIES LIMITED

STANDALONE CASH FLOW FOR DIVI'S LABORATORIES LIMITED

CONSOLIDATED BALANCE SHEET FOR DIVI'S LABORATORIES LIMITED

STANDALONE BALANCE SHEET FOR DIVI'S LABORATORIES LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR DIVI'S LABORATORIES LIMITED

FINANCIAL RATIOS (STANDALONE) FOR DIVI'S LABORATORIES LIMITED

SHARE HOLDING PATTERN FOR DIVI'S LABORATORIES LIMITED

PEER COMPARISON FOR DIVI'S LABORATORIES LIMITED

CORPORATE ACTIONS FOR DIVI'S LABORATORIES

CORPORATE ANNOUNCEMENTS FOR DIVI'S LABORATORIES

INSIDER TRADING FOR DIVI'S LABORATORIES

BULK BLOCK DEALS FOR DIVI'S LABORATORIES LIMITED

DIVIDEND BY DIVI'S LABORATORIES LIMITED

SPLIT / BONUS BY DIVI'S LABORATORIES LIMITED